Kornimate/medical-research-clean huggingface dataset:
covid-19 associated pulmonary aspergillosis (capa) and other invasive fungal infections (ifi)

Conditions: Covid19; Aspergillosis; Fungal Infection

Summary: the purpose of this study is to identify the number of individuals with severe covid who require ventilator support and who develop serious fungal infections. the study is an observational study, meaning that we are not providing any intervention that does not involve usual standard of care. our chief goal is to find evidence of fungal infection by using traditional, approved methods of diagnosis, but by applying these methods in the same way and frequency among all study participants. we will be looking especially for evidence of a fungal infection known as aspergillus, which can causes a serious lung infection called invasive aspergillosis (ia).

covid-19 is a disease caused by infection with the novel coronavirus sars-cov2 which emerged in late 2019 in wuhan, china (1). this illness is associated with viral prodromal symptoms, then subsequently fever, cough, and shortness of breath (1). in a subset of patients, lower respiratory tract infection associated with respiratory failure develops. among these patients, progression to severe respiratory failure and ards requiring ventilator support has occurred in an alarming number of patients at rates that are many-fold higher than what is typically associated with seasonal influenza a or b (2). one of the most feared complications of post-influenza respiratory failure is the development of invasive pulmonary aspergillosis which may occur in as many as 15-20% of those requiring ventilator support (based on european data) (3-6). among those developing ia following influenza a or b, mortality of 50% or greater is reported (3-6).

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older at the time of enrollment * sars-cov2 positivity by pcr with respiratory failure requiring mechanical ventilation for at least 72 hours * prior therapy with antifungals, including prophylaxis, is not an exclusion. exclusion criteria: * life expectancy of less than 72 hours as determined by the site investigator. * expected to be weaned from mechanical ventilation in next 24 hours * care received in any setting other than an intensive care unit (icu) at the time of enrollment

Keywords: covid19 aspergillosis fungal capa
multi detector-row computed tomography (mdct) calcium score of heart transplanted patients

Conditions: Coronary Artery Disease

Summary: the purpose of the study is to determine if calcium score can be used as a predictor of coronary artery disease in heart transplanted patients, as it is used in non-transplanted persons.

several studies have shown that a negative calcium score is a strong independent negative predictor of coronary artery disease (cad). cad in heart transplants (htx) differs from cad lesions in native hearts. the aim of this study is to see if there is a similar relation between coronary artery calcium and cad in transplanted hearts as in native hearts.

Eligibility criteria:
inclusion criteria: * heart transplanted patient * aged 18 or above. exclusion criteria: * pregnancy * atrial fibrillation * severe heart failure new york heart association (nyha) class iv * severe pulmonary disease making the patient unable to hold his/her breath for more than 10 seconds.

Keywords: coronary calcium score coronary artery disease cardiac transplantation coronary calcium score in heart transplanted patients coronary artery disease in heart transplanted patients
does point of care ultrasound change needle insertion location during routine bedside paracentesis?

Conditions: Ascites; Paracentesis; Point of Care Ultrasound (POCUS)

Summary: paracentesis is a bedside procedure in which a needle is inserted into a patient's peritoneum in order to obtain ascitic fluid. this is a safe bedside procedure with very low risks of complications that is usually performed using physical exam maneuvers to determine the site of needle insertion. point of care ultrasound (pocus) technology has improved the safety of central venous catheter insertion and thoracentesis, yet the data on safety in paracentesis is equivocal. in a practical study, we aim to determine if pocus will change the needle insertion site over the traditional anatomic landmarking method. operators will landmark for paracentesis using conventional physical exam and then utilize pocus to determine if there is a more optimal site. the primary endpoint will be whether pocus yielded a change in the needle insertion site, as defined by a location greater than 5cm from the anatomic site, at least 20% of the time. the results will further our understanding of pocus in improving procedural safety, thereby adding to the currently limited literature on this topic. furthermore, this study will inform residency training programs about the utility in pocus training for paracentesis and may advocate for the availability of pocus devices to physicians performing this procedure.


Eligibility criteria:
this is in effort to capture routine paracentesis cases. inclusion criteria: * participants scheduled to have either a diagnostic of therapeutic paracentesis. * participants can be either inpatients under the care of general internal medicine, or outpatients under the care of gastroenterology or general internal medicine. * operators will be recruited on a volunteer basis and will include medical residents or subspecialty fellows with knowledge of pocus for paracentesis purposes, either through core residency programs or more advanced training. exclusion criteria: * loculated ascites * current anticoagulation * hemodynamic instability * bowel obstruction * pregnancy * abdominal wall cellulitis * platelet count \<20

Keywords: paracentesis point of care ultrasound (pocus)
prevention of functional and cognitive impairment through a multicomponent exercise program

Conditions: Frailty; Disability Physical; Hospital Acquired Condition

Summary: the hospitalized elderly patient is conditioned by a series of circumstances unrelated to the pathological process itself that caused hospital admission and that usually worsen the results of hospitalization. in fact, the implementation of care models different from the traditional ones has shown a clear benefit in the functional results of these patients in the short and medium term. however, the components of these models that explain these better results have not been differentially evaluated. some examples of these circumstances are the usual orders of absolute rest without any objective criteria for patients who are able to wander, the perpetuation of continuous fluid therapy, physical and chemical restraints, unnecessary permanent probes, etc. on numerous occasions, hospitalized elderly patients spend most of their time in bed, reaching even more than 83% of bedridden compared to 4% of those who stand up or are walking. the average time that a geriatric patient walks during their hospitalization ranges from 7 to 43 minutes/day. this population, by having their functional and physiological reserve reduced, are more vulnerable to the effects, for example, of bedridden, which range from functional loss or cognitive impairment, to longer stays, mortality and institutionalization, worse emotional situation, delirium, deconditioning, aspirations, pressure ulcers, and falls, decreased caloric intake, social isolation, poorer quality of life, and greater use of health-related resources. this study is a multicenter randomized clinical trial to be conducted in the acute care for elderly (ace) units of three tertiary hospitals in spain - complejo hospitalario de navarra (chn), hospital central de la cruz roja de madrid (hccrm) and complejo hospitalario universitario of albacete (chua). after randomization, the research team (physiotherapist, sport science specialist and geriatrician) will together perform the baseline measurement and follow-up visits of functional, pharmacological, comorbidity and cognitive assessment, as well as of mobility and strength evaluations. the intervention will consist of a multicomponent exercise training programme, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. during the training period, patients will be trained in 20 min sessions twice a day (morning and evening).


Eligibility criteria:
inclusion criteria: * \> 75 years * barthel index ≥60 points * able to ambulate (with/without assistance) * sing the informed consent * able to communicate exclusion criteria: * expected length of stay \<6 days * terminal illness * very severe cognitive decline (i.e., gds 7) * uncontrolled arrhythmias, acute pulmonary embolism and myocardial infarction, or extremity bone fracture in the past 3 months.
risk factors for sudden unexplained death in epilepsy

Conditions: SUDEP

Summary: the main purpose of this study is to develop a north american registry for sudep cases; requesting family members of epilepsy patients who died suddenly of unclear causes (sudep) to contact the study team. the family members who decide to participate in the study will be asked to complete a brief telephone interview about their loved one's epilepsy and seizure history and the circumstances of his or her death. if the death has occurred within the past 24 hours, and the family is willing to consider donating tissue to the study, the subject will be transferred to the autism tissue program, and the remainder of the phone interview will be conducted at a later time. in addition to the phone interview, the family will be asked to provide access to the deceased's medical records. any costs involved in obtaining medical records will be covered by the study, and all medical information will remain completely confidential.

sudep stands for sudden unexplained death in epilepsy; a witnessed or unwitnessed, non-traumatic and non-drowning death occurring in benign circumstances, in a person with epilepsy with or without evidence of a seizure and excluding documented status epileptics (seizure duration of 130mins or longer, or seizures without recovery in between), in which a postmortem examination does not reveal a cause of death. sudep is not a cause of death so much as it is a descriptive term for a category of unexplained deaths in people with epilepsy or epilepsy-related conditions. little is known about sudep and its mechanisms and risk factors. one of the main objectives of this study is to investigate the role of various risk factors in the development of sudden unexplained death in patients with epilepsy, with a particular focus on the role of antiepileptic medications. in addition, we want to elucidate the pathophysiologic mechanisms leading to sudep.

Eligibility criteria:
inclusion criteria sudep group subjects diagnosed with epilepsy whose cause of death was sudden and unexplained, and whose families are willing to participate, will be included in the study. control group for the control group, we will include any patient diagnosed with epilepsy currently in the care of the nyu comprehensive epilepsy center, willing and able to participate in the study.

Keywords: epilepsy seizures mortality sudep risk factors
scapular motor control for chronic mechanical neck pain

Conditions: Chronic Mechanical Neck Pain

Summary: the purpose of this study is to investigate the effect of motor control training using scapular pnf exercise on neck pain, function, proprioception, and scapular muscle strength in patients with chronic mechanical neck pain.

chronic mechanical neck pain (cmnp) is defined as generalized neck and/ or shoulder pain for more than 3 months with symptoms provoked by neck movement, neck postures, or palpation of the cervical muscles . regional interdependence (ri) is defined as the concept that a patient's primary musculoskeletal symptom(s) may be directly or indirectly related or influenced by impairments from various body regions and systems regardless of proximity to the primary symptom(s)'. changes in scapular posture and alteration of muscle activation patterns of scapulothoracic muscles are cited as potential risk factors for neck pain the structural connectivity of the cervical spine and scaopulothorathic muscles . the bones and muscles of the cervical spine and the shoulders are connected to each other mechanically, thus a continuously applied mechanical load on the shoulders directly increases the load on the cervical region, which may cause joint and ligament pain scapular malalignment can contribute to prolonged compressive loading of the posterior cervical structures . it has been suggested that abnormal joint stress affects the firing of cervical afferents, leading to changes in proprioceptive function. moreover, pain leads to changes in motor control . we believe that scapular motor control exercises using pnf technique may help to restore normal alignment and reverse this vicious circle pnf technique is based on movement patterns to facilitate and correct sensory-motor function it has been suggested that pnf correct the impaired impulses emerging from proprioceptive receptors in the muscle. therefore, it decreases pain and desires to improve the strength of muscles. pnf position renders a greater amount of sensory input coming from the periphery than that in the neutral position .the purpose of this study is to investigate the effect of motor control training using scapular pnf exercise on neck pain, function, proprioception, and scapular muscle strength in patients with chronic mechanical neck pain.

Eligibility criteria:
inclusion criteria: * -the subject will be referred from orthopedic surgeon with diagnosis of cmnp. * subjects with cmnp of more than 3 months with age range between 18 and 45 years * subjects having a baseline ndi score of at least 20% (10 points) * at least 3/10 pain intensity on vas exclusion criteria: * spinal canal stenosis. * traumatic injury to the cervical spine. * previous surgery related to cervical spine. * hypermobility of the cervical spine, * any red flags e.g. cervical instability, history of cancer, long use of corticosteroids. * presence of an inflammatory rheumatologic disease,
ifm 99-02 thalidomide in myeloma

Conditions: Multiple Myeloma

Summary: principal objective is to evaluate the impact of thalidomide to prolong the duration of response after autologous transplantation for myeloma


Eligibility criteria:
inclusion criteria: * de novo myeloma * according to durie and salmon classification stage ii, iii and stage i with a lytic bone lesion * patients from 18 to 65 years old * beta2microglobulin \< 3 mg/l or del13 absent * signed informed consent * eligible for transplantation exclusion criteria: * peripheral neurological toxicities * uncontrolled or severe cardiovascular disease * other malignancy except basocellular carcinoma or figo stage i carcinoma of the cervix * patient who received biphosphonate during the last 60 days * renal failure definited as creatinine \> 150 µmol/l * patient with obvious vascular cerebral medical history * liver dysfunction definited as bilirubin \> 35 µmol/l or asat, alat, pal \> 4n * respiratory dysfunction * hiv + * patient who refused to use an acceptable barrier method for contraception

Keywords: myeloma autologous transplantation maintenance therapy thalidomide
interleukin and autoantibodies in myasthenia gravis.

Conditions: Myasthenia Gravis

Summary: myasthenia gravis is a b-cell-mediated autoimmune disorders causing muscle weakness due to defective synaptic transmission at the neuromuscular junction caused by autoantibodies to acetylcholine receptors in (∼85%), muscle specific kinase in 6% and low-density lipoprotein receptor-related protein 4.the detection of these autoantibodies is very important not only in the diagnosis, but also for the stratification of myasthenia gravis patients into respective subgroups. these groups can differ in clinical manifestations, prognosis and response to therapies which become relevant for the development of antigen-specific therapies, targeting only the specific autoantibodies involved in the autoimmune response.

follicular t cells play a vital role during autoimmune disorders. the enhanced number or activation of these cells results in hyperproliferation of autoreactive b cells and overproduction of antibodies. interleukin-37 is a newly identified immune-suppressive factor. it acts as an inhibitor of inflammation and plays an important regulatory role in both innate and adaptive immune responses. in myasthenia gravis, cluster of differentiation 4+ t cell is the dominant cellular source for interleukin-37 production directed to t follicular helper and b cells .it represses cell proliferation and secretion of autoantibody indicating that interleukin-37 is a critical regulatory factor. the immunosuppressive features of interleukin 37 contributing to autoimmune diseases are important and still poorly investigated. for this reason, the present study is designed to detect the level of expression of interleukin 37 in myasthenia gravis patients and its correlation with autoantibodies serum levels and disease severity.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of myasthenia gravis. 2. willingness to sample collection. exclusion criteria: 1. history of chronic psychiatric or neurological disorder other than myasthenia gravis that can produce weakness or fatigue. 2. severe systemic illness affecting life-expectancy ( chronic liver or kidney diseases). 3. history of autoimmune diseases, connective tissue diseases, , or genetic diseases. 4. patients on large dosage of immune-suppressive treatment or intravenous immunoglobulin in the recent 3 months.
evaluation of the detection of atrial fibrillation by a wearable dynamic ecg recorder

Conditions: Atrial Fibrillation

Summary: a randomized, crossover trial is conducted to evaluate consistency atrial fibrillation diagnosis between the wearable dynamic ecg recorder and the control device. in this investigation, the following indicators is also evaluated: 1. sensitivity and specificity of the ecg app algorithm in detecting atrial fibrillation compared with physician-adjudicated gold standard ecg recorder. 2. waveform qualitative assessment 3. safety incident assessments. 114 subjects (60 healthy subjects in phase i and 54 subjects with atrial fibrillation diagnosis in phase ii) are enrolled in the investigation according to the criteria.


Eligibility criteria:
inclusion criteria: * - all study participants must be able to provide written informed consent prior to study procedure. this study has 2 phases. phase 1: * health conscious individuals * \> 18 years of age phase 2: * \> 18 years of age * non critical patients ever diagnosed with atrial fibrillation exclusion criteria: * • \< 18 years old * unable to consent phase 1: * \> 80 years of age * previous history of cardiac disease (e.g., atrial fibrillation, myocardial infarction, congestive heart failure) * current status of non-sinus heart rhythm phase 2: - critical patients
pain associated with endometriosis

Conditions: Endometriosis

Summary: this study will evaluate the efficacy and safety of an investigational medication compared with placebo in the treatment of pain associated with endometriosis.


Eligibility criteria:
inclusion criteria: * menstruating female 18-50 years of age, * regular cycle length of 21 to 35 days with menstrual bleeding that typically lasts no more than 7 days, * has pain associated with endometriosis, * has a documented history consistent with endometriosis, exclusion criteria: * is pregnant or lactating, * has a history of or has active thrombosis
correlation of lung biopsy, bal, and high resolution ct scan in lung transplantation

Conditions: Bronchiolitis Obliterans Syndrome

Summary: a major source of graft failure and dysfunction in lung transplantation is known to be bronchiolitis obliterans (bo)and its clinical correlate called bronchiolitis obliterans syndrome(bos). in fact, bos is the leading cause of death in lung recipients beyond one year post transplant. currently, our ability to assess lung injury after transplant is less than ideal. the purpose of this study is to use new computerized tomography(ct) technology, specifically , 64 bit acquisition, to detect and predict the onset of lung injuries, with the hope of finding better therapies that currently exist.

total enrollment : 10 lung transplant patients will undergo ct scans before scheduled bronchoscopies which are routinely performed at 1, 3, 6, 9, and 12 months post transplant. imaging will be done with the newest generation scanner, with intent to analyze all pertinent areas of the lung for pathology, but especially the bronchial anastomoses, the lung parenchyma with focus on gas exchanging lobules of the lung, and any suspected abnormalities from physical exam, laboratory tests, or prior chest xray. ct imaging will precede bronchoscopy and biopsy so that ct interpretation will be unencumbered by changes due to the bronchoscopic procedure.

Eligibility criteria:
inclusion criteria: * lung transplant patients who are at least 18 years of age. * all patients must be able to give written informed consent. exclusion criteria: * lung transplant patients who are unable to undergo a ct scan. * lung transplant patients who are unable to give informed consent.

Keywords: bronchiolitis obliterans syndrome
albumin-bound paclitaxel and gemcitabine in patients with untreated stage iv or recurrent squamous cell lung cancers

Conditions: Lung Cancer; Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Summary: the purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. the investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this regimen. this combination of drugs is not a standard therapy for patients with squamous cell lung cancers. however, each of these drugs, when given alone or with other chemotherapies, is fda-approved for the treatment of this disease.


Eligibility criteria:
inclusion criteria: * histologically confirmed squamous cell lung cancer * newly diagnosed untreated stage iv and/or recurrent after adjuvant therapy with metastatic disease * patients previously treated with immune checkpoint inhibitor therapy are eligible * measurable disease as per recist 1.1 * greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy. * age ≥ 18 years * eastern cooperative oncology group (ecog) performance status of 0-1 * women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatment * negative serum or urine β-hcg pregnancy test at screening for patients of childbearing potential * \< grade 2 pre-existing peripheral neuropathy (per ctcae) * marrow and organ function as follows: * anc ≥ 1500 cells/mm3 * platelets \> 100,000 cells/mm3 * hemoglobin\>9g/dl * creatinine clearance ≥ 40ml/min * bilirubin ≤ 1.5 mg/dl * ast/alt≤2.5 x upper limit of normal range (uln), * alkaline phosphatase ≤ 2.5 x upper limit of normal, unless bone metastasis in present in the absence of liver metastasis exclusion criteria: * prior treatment with albumin-bound paclitaxel or gemcitabine * prior systemic anticancer therapy for advanced squamous cell lung cancer * untreated brain metastasis. patients with treated brain metastases who are off steroids are eligible * peripheral neuropathy greater than grade 1 * malignancies within the past 5 years other than non-melanoma skin cancer or insitu cervical cancer status post treatment * patients with other serious medical illnesses including, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements * class iii or iv congestive heart failure by new york heart association

Keywords: albumin-bound paclitaxel gemcitabine 15-054